BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the successful completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). Deupirfenidone is being advanced by Celea Therapeutics ...

BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia. ...

Core Insights - PureTech has presented new data from the Phase 2b open-label extension study of Deupirfenidone, indicating its potential to become a new standard of care for Idiopathic Pulmonary Fibrosis (IPF) [1] Group 1: Study Findings - The data supports the efficacy and safety profile of Deupirfenidone in treating IPF, suggesting significant clinical benefits [1] - The study results demonstrate a favorable outcome in terms of lung function preservation and quality of life for patients [1] Group 2: Market Implications - If approved, Deupirfenidone could address a significant unmet need in the IPF treatment landscape, potentially capturing a substantial market share [1] - The findings may influence treatment guidelines and physician prescribing behavior, positioning Deupirfenidone as a preferred option for IPF management [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...

Core Insights - Lytus Technologies Holdings PTV. Ltd. reported significant revenue growth and improved profitability for the six months ended September 30, 2024, with a focus on innovation and operational efficiency [1][3] Financial Performance - Revenue for the six-month period reached $12.01 million, marking a 24% increase from $9.66 million in the same period of the previous year [5] - The company achieved a net profit of $648,972, reflecting a profit margin of 5.40%, which is a 151% increase compared to a net loss of $1,281,940 in the prior year [5] - Positive operating cash flow was generated amounting to $182,070 [5] Asset and Liability Management - Total assets increased to $34.17 million, an 8.3% rise from $31.56 million in the previous year [5] - Total liabilities decreased to $15.24 million, down 2.2% from $15.58 million in the same period last year [5] Strategic Initiatives - The company is expanding into broadband services, particularly in Telangana and Andhra Pradesh, which is expected to enhance revenue further [3] - Lytus Technologies has a captive base of 4 million subscribers and is focused on launching new value-added services to meet consumer and business demands [3][4]

Company Overview - Lytus Technologies Holdings, Ltd. has launched Lytus Healthcare, a fully owned subsidiary aimed at transforming patient care and healthcare accessibility in India [1][2] - The company is positioned to leverage its digital innovation strategy to enhance essential services for over 4 million users [2][10] Industry Growth - India's healthcare sector is projected to grow at a 22% CAGR, presenting significant opportunities for Lytus Healthcare to address service delivery gaps through AI-driven patient management solutions [2][3] Financial Performance - Lytus reported a 26% revenue growth for the first half of FY2025, driven by increased adoption of its digital platform services and strategic expansion efforts [3][4] - The company has secured an initial $6 million in funding under a Standby Equity Purchase Agreement (SEPA), with access to up to $100 million for growth capital over the next three years [4][5] Strategic Initiatives - Lytus is committed to sustainable growth while investing in next-generation solutions that enhance customer experience and shareholder value [4][5] - The company aims to deepen its presence in emerging markets and pioneer next-generation technology solutions across various sectors, including HealthTech, fintech, and AI [5][10]

Company Overview - Lytus Technologies has launched a fully owned subsidiary, Lytus HealthTech, aimed at transforming the healthcare landscape in India [1] - The company is focused on integrating advanced technologies with personalized patient care solutions to address challenges in the Indian healthcare system [1][2] Industry Context - India's healthcare system is projected to grow at a 22% CAGR, facing challenges in accessibility, speed, and integration across the patient care journey [2] - The need for a unified healthcare system in India is emphasized, particularly to address inefficiencies in service delivery, especially in rural and underserved regions [3] Platform Features - The Lytus HealthTech platform aims to provide a personalized patient experience, optimizing clinical workflows to empower healthcare professionals [2][4] - AI-powered analytics and real-time data insights are integral to the platform, enabling informed, data-driven decisions for better patient outcomes [2][5] Operational Goals - The platform is designed to enhance decision-making, reduce manual errors, and speed up clinical processes, improving both patient experience and operational efficiency [4] - Lytus HealthTech plans to roll out its ecosystem over the next two years and is actively recruiting talent in healthcare technology, operations, and AI [4][5] Economic Impact - The system is expected to drive economic benefits by increasing productivity and reducing operational costs for healthcare providers, allowing them to serve more patients without compromising care quality [4] - The scalable and adaptable nature of the platform is intended to grow alongside India's expanding healthcare needs [4]

Financial Performance - The company reported a total income of $23,003,342 for the fiscal year ended March 31, 2024, representing an increase of $3,610,013 or 19% compared to $19,393,329 in the previous year[302][303]. - Revenue from contracts with customers increased by $2,355,591 or 12%, driven primarily by a rise in carriage and placement fees by $2,004,044 or 59% and subscription income by $1,024,310 or 7%[304]. - The Company reported an increase in other income by $1,254,422 or 326%, primarily due to a provision for warrants liabilities no longer required, which increased by $1,274,773 or 353%[307]. - For the fiscal year ended March 31, 2024, total revenue was $23,003,342, an increase of $3,610,013 or 19% from $19,393,329 in the previous year[328]. - Revenue from contracts with customers was $21,363,775, up $2,355,591 or 12% compared to $19,008,184 for the fiscal year ended March 31, 2023[329]. - Net income for the year ended March 31, 2024, was $1,439,610, a 33% increase from $1,078,491 in the previous year[328]. - The company reported a basic income per common share of $0.68 for the fiscal year ended March 31, 2024, compared to a loss of $2.67 in the previous year[328]. Expenses and Costs - Cost of revenue for the year ended March 31, 2024, was $16,762,580, an increase of $2,878,289 or 21% from $13,884,291 in the previous year, mainly driven by a $2,739,623 or 22% increase in the cost of materials consumed[308]. - Staffing expenses rose to $844,098 for the fiscal year ended March 31, 2024, reflecting an increase of $210,119 or 33% from $633,979 in the prior year, attributed to higher salaries due to the deployment of device boxes[309]. - Amortization and depreciation costs increased to $926,484, representing a rise of $230,260 or 33% from $696,224 in the previous fiscal year, primarily due to additions in property, plant, and equipment[311]. - Finance and other costs decreased significantly to $638,957 for the fiscal year ended March 31, 2024, down by $1,571,447 or 71% from $2,210,404 in the previous year, due to repayment of borrowings and no claims on warrants liability[312]. - The Company incurred Broadcaster/Subscription Fees of $1,225,922, an increase of $134,222 or 12% from $1,091,700 in the previous year[308]. - Legal and professional expenses decreased to $386,622, down by $446,457 or 54% from $833,079 in the prior year, as last year's expenses were elevated due to listing and related professional fees[309]. - Other operating expenses increased to $2,643,948, reflecting a rise of $376,683 or 17% from $2,267,265 in the previous year, with the increase being marginally related to the Sri Sai business[311]. Cash Flow and Financing - Net cash provided by operating activities for the year ended March 31, 2024, was $886,034, a decrease from $1,153,335 in the previous year[343]. - Net cash used in investing activities was $3,651,681 for the year ended March 31, 2024, compared to $12,920,014 for the year ended March 31, 2023[346]. - Net cash provided by financing activities was $2,705,230 for the year ended March 31, 2024, down from $11,655,402 in the previous year[347]. - The principal amount of current debt as of March 31, 2024, was $13,975,499, a decrease from $15,258,547 as of March 31, 2023[348]. - The company expects to utilize free cash flow and cash on hand for business growth, strategic opportunities, and potential mergers and acquisitions[349]. Strategic Initiatives - The company is beta testing remote patient monitoring devices in Telangana, with a subscription-based service expected to launch in the second half of 2024[284]. - Plans to set up local health centers and diagnostic centers in India are being developed, with a rollout expected to commence in the second half of 2024 and take approximately 24 months to complete[284]. - The company aims to leverage India's e-commerce boom and telemedicine regulations through acquisitions, enhancing its business model with experienced management teams[288]. - Lytus Studios is in discussions to create curated content for its platform, with initial deployment expected for its customer base in India[284]. - The company has obtained an Internet Service Provider License to offer Broadband/Internet services alongside traditional cable services, aiming to enhance Revenue Per User[356]. - The company incurred approximately INR 250,000 ($3,150) to apply for a trademark registration, indicating a shift towards investing in research and development[351]. - The company is actively reviewing potential acquisitions to improve operational efficiency and achieve appropriate return targets[350]. Market Risks and Financial Policies - The company is exposed to market risks including foreign currency fluctuations and interest rate changes, primarily operating in India and the United States[338]. - The company is exposed to foreign currency exchange rate risk due to operations primarily in India and the United States, affecting revenue presented in U.S. dollars[339]. - The company continues to monitor inflation impacts and may not fully offset higher costs through price increases, which could harm financial results[342]. - The Company did not have any off-balance sheet arrangements that required disclosure, and it has not entered into any financial guarantees or derivative contracts related to its shares[316][317]. - The Company’s cost recognition policy states that costs and expenses are recognized when incurred, classified according to their primary functions[308]. - The company recognizes impairment losses and reversals in accordance with IFRS, ensuring that the carrying amount does not exceed the amount that would have been determined without prior impairment losses[362]. - Upon loss of control over a subsidiary, the assets and liabilities, including goodwill, are derecognized, and any retained equity interest is remeasured at fair value[363]. - Share warrants are classified as either equity instruments or derivative liabilities based on specific terms, with those requiring "net cash settlement" classified as financial liabilities[364]. - Outstanding warrants are recognized as a warrant liability on the balance sheet and measured at fair value at inception, with subsequent re-measurements recognized in profit or loss[365].

Core Viewpoint - Lytus Technologies (NASDAQ:LYT) is experiencing significant stock price movement with a notable increase in trading volume despite the absence of any clear news or analyst coverage [1][2]. Group 1: Stock Performance - LYT stock has risen by 109.1% as of Tuesday morning [4]. - Over 8.5 million shares of LYT have been traded, a substantial increase compared to the daily average of approximately 77,000 shares [2]. Group 2: Market Characteristics - Lytus Technologies is classified as a penny stock, indicated by its low trading volume and a market capitalization of $2.607 million [2]. - The company's float is 426,160 shares, which contributes to its volatility [2][3]. Group 3: Trading Behavior - The heavy trading activity may suggest speculative interest from retail traders, potentially buying on a recent dip or engaging in pump-and-dump strategies [3].

Core Insights - Lytus Technologies has launched Radio Room, an audio streaming platform aimed at the Indian diaspora, offering diverse audio dramas across various genres [1][6] - The launch signifies Lytus' strategic entry into the audio OTT market, with plans to expand into original film and television content in multiple Indian languages [2][6] - Lytus aims to leverage its existing customer base of 4 million subscribers to rapidly scale Radio Room's operations and reach [3][7] Company Overview - Lytus Technologies is positioned as a forward-thinking platform services entity focused on technological innovation and enhancing user experiences [6][8] - The company emphasizes a customer-centric approach, continuously innovating to meet the evolving needs of its clients [3][8] Market Positioning - Radio Room is expected to become a significant player in the audio streaming sector, transforming audience engagement with digital content [2][7] - The platform plans to target a diverse audience by offering content in various Indian regional languages and expanding into international languages [7]